Cannabinoid hyperemesis syndrome is increasingly important as cannabis use grows and THC potency rises | Research

The takeaway

A Federal Practitioner review highlighted that converging factors of cannabis legalization, increasing use, and rising THC potency make cannabinoid hyperemesis syndrome an increasingly important condition for clinicians to recognize.

Read this if you're a healthcare provider who might encounter cannabinoid hyperemesis syndrome.

Converging factors: legalization + increased use + higher THC potency = more CHS cases

What the researchers found

The review from a federal healthcare publication emphasized that cannabinoid hyperemesis syndrome (CHS) sits at the intersection of three converging trends: legislative efforts expanding cannabis access, increasing prevalence of cannabis use, and rising THC potency. These factors combine to make CHS a more commonly encountered but still frequently missed diagnosis.

Why it matters

CHS is often misdiagnosed or unrecognized, leading to repeated ER visits, unnecessary testing, and delayed treatment. Healthcare providers in federal settings (VA, military, public health) need awareness as cannabis use patterns evolve among their patient populations.

The numbers in context

The review highlights three converging factors: legislative changes, increasing prevalence, and THC toxicity.

How the study worked

Clinical review article published in a federal healthcare practitioner journal aimed at VA, DoD, and PHS healthcare professionals.

What this study cannot tell us

Brief overview article with a very concise abstract. Limited detail on specific clinical recommendations or evidence base.

How to read the evidence

Brief clinical overview. Provides awareness but limited detailed evidence review.

When this study was published

Published in 2017. CHS awareness in clinical practice has continued to improve.

The bigger picture

The publication venue, Federal Practitioner (serving VA, DoD, and PHS), is notable. Federal healthcare systems serve populations with distinct cannabis use patterns, and clinician education in these settings is essential for recognizing CHS.

Questions still open

How common is CHS in federal healthcare patient populations? Are VA and military healthcare providers adequately trained to recognize CHS? Does the federal scheduling of cannabis affect CHS reporting and diagnosis?

Common questions

What is cannabinoid hyperemesis syndrome?

CHS is a condition where chronic cannabis users develop recurrent episodes of severe nausea, vomiting, and abdominal pain. It is paradoxical because cannabis is often used to treat nausea. Symptoms resolve completely when cannabis use stops.

Why is CHS becoming more common?

Three factors are converging: more states legalizing cannabis, more people using it, and cannabis products becoming more potent (higher THC). Higher THC exposure may increase the likelihood of developing CHS.

Read the original research

Cannabinoid Hyperemesis Syndrome.

Federal practitioner : for the health care professionals of the VA, DoD, and PHS, 34(10), 33-36

View on PubMed ↗

Citation

Fleming, J Eric; Lockwood, Sean. (2017). Cannabinoid Hyperemesis Syndrome.. Federal practitioner : for the health care professionals of the VA, DoD, and PHS, 34(10), 33-36.